Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
raleigh-durham blog main
74
×
san francisco blog main
life sciences
national top stories
new york blog main
raleigh-durham top stories
boston blog main
san francisco top stories
san diego blog main
seattle blog main
wisconsin blog main
boston top stories
detroit blog main
texas blog main
texas top stories
national
new york top stories
seattle top stories
biotech
detroit top stories
indiana blog main
san diego top stories
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
indiana top stories
fda
clinical trials
cancer
startups
deals
merck
pfizer
eli lilly
novartis
bristol-myers squibb
amgen
gene therapy
celgene
What
roundup
bio
drug
new
cancer
fda
week
life
drugs
medical
science
companies
ipo
medicine
company
disease
news
pharmaceutical
annual
approval
conference
days
million
moves
nash
patients
plan
prices
sciences
american
biotech
crispr
healthcare
help
house
known
long
plans
price
society
Language
unset
unknown
Current search:
" raleigh-durham blog main "
×
@xconomy.com
4 months ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
5 months ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 months ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
5 months ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
10 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
11 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
1 year ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
1 year ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
1 year ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
1 year ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
1 year ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
1 year ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
1 year ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
1 year ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
1 year ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
1 year ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
1 year ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
1 year ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
1 year ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com
1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
1 year ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
1 year ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
1 year ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
1 year ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
1 year ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com
1 year ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
1 year ago
Review: Inside the House of Lies at Theranos
@xconomy.com
1 year ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
1 year ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
1 year ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
1 year ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
1 year ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
1 year ago
Hatteras Launches New Fund With $94M for Life Science Investments
@xconomy.com
1 year ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
1 year ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
1 year ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
2 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
2 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
2 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
2 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
2 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
2 years ago
San Antonio Life Science Business Acelity Cuts 260 Jobs in Texas, NC
@xconomy.com
2 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
First
Prev
Page 1
(current)
Next
Last